Corvus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CRVS Corvus Pharmaceuticals Inc
INKAW KludeIn I Acquisition Equity Warrant Exp 08 July 2027 *W EXP 07/08/2027
ALC Alcon AG
BEN Franklin Resources Inc
REGN Regeneron Pharmaceuticals Inc
PSNL Personalis Inc
CORR CorEnergy Infrastructure Trust Inc
SBRA Sabra Health Care REIT Inc
ZI ZoomInfo Technologies Inc
ATNI ATN International Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

Price
Delayed
$1.94
Day's Change
-0.075 (-3.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.10
Day's Low
1.92
Volume
(Heavy Day)

Today's volume of 556,474 shares is on pace to be much greater than CRVS's 10-day average volume of 439,827 shares.

556,474

There is no peer information for CRVS.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.